Cargando…

A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy

PURPOSE: Oral mucositis is a common side effect of concurrent chemoradiotherapy (CCRT). This study aimed to determine whether cognitive behavioral therapy (CBT) could help prevent oral mucositis during chemoradiation therapy for locoregional advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MA...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Li-li, Xiao, Shuai, Jiang, Cui-hong, Wu, Xiang-wei, Liu, Wen, Fan, Chang-gen, Ye, Xu, Zhao, Qi, Wu, Wen-qiong, Li, Yan-xian, Wang, Hui, Liu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282775/
https://www.ncbi.nlm.nih.gov/pubmed/37350940
http://dx.doi.org/10.3389/fonc.2023.1143401
_version_ 1785061193126248448
author He, Li-li
Xiao, Shuai
Jiang, Cui-hong
Wu, Xiang-wei
Liu, Wen
Fan, Chang-gen
Ye, Xu
Zhao, Qi
Wu, Wen-qiong
Li, Yan-xian
Wang, Hui
Liu, Feng
author_facet He, Li-li
Xiao, Shuai
Jiang, Cui-hong
Wu, Xiang-wei
Liu, Wen
Fan, Chang-gen
Ye, Xu
Zhao, Qi
Wu, Wen-qiong
Li, Yan-xian
Wang, Hui
Liu, Feng
author_sort He, Li-li
collection PubMed
description PURPOSE: Oral mucositis is a common side effect of concurrent chemoradiotherapy (CCRT). This study aimed to determine whether cognitive behavioral therapy (CBT) could help prevent oral mucositis during chemoradiation therapy for locoregional advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: Between July 15, 2020, and January 31, 2022, a randomized controlled phase II trial was conducted. Eligible patients (N=282, 18-70 years old) with pathologically diagnosed LA-NPC were randomly assigned to receive CBT or treatment as usual (TAU) during CCRT (computer-block randomization, 1:1). The primary endpoints were the incidence and latency of oral mucositis. RESULTS: The incidence of oral mucositis was significantly lower in the CBT group (84.8%; 95% confidence interval [CI], 78.7%-90.9%) than in the TAU group (98.6%; 95% CI, 96.6%-100%; P<0.001). The median latency period was 26 days and 15 days in the CBT and TAU groups, respectively (hazard ratio, 0.16; 95% CI, 0.12-0.22; P<0.001). CBT significantly reduced ≥ grade 3 oral mucositis (71.9% vs. 22.5%, P<0.001), dry mouth (10.8% vs. 3.7%, P=0.021), dysphagia (18% vs. 5.1%, P=0.001), and oral pain (10% vs. 3.6%, P=0.034) compared with TAU. Patients receiving CBT and TAU during CCRT had similar short-term response rates. CONCLUSIONS: CBT reduced the occurrence, latency, and severity of oral mucositis in patients with LA-NPC during CCRT.
format Online
Article
Text
id pubmed-10282775
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102827752023-06-22 A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy He, Li-li Xiao, Shuai Jiang, Cui-hong Wu, Xiang-wei Liu, Wen Fan, Chang-gen Ye, Xu Zhao, Qi Wu, Wen-qiong Li, Yan-xian Wang, Hui Liu, Feng Front Oncol Oncology PURPOSE: Oral mucositis is a common side effect of concurrent chemoradiotherapy (CCRT). This study aimed to determine whether cognitive behavioral therapy (CBT) could help prevent oral mucositis during chemoradiation therapy for locoregional advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: Between July 15, 2020, and January 31, 2022, a randomized controlled phase II trial was conducted. Eligible patients (N=282, 18-70 years old) with pathologically diagnosed LA-NPC were randomly assigned to receive CBT or treatment as usual (TAU) during CCRT (computer-block randomization, 1:1). The primary endpoints were the incidence and latency of oral mucositis. RESULTS: The incidence of oral mucositis was significantly lower in the CBT group (84.8%; 95% confidence interval [CI], 78.7%-90.9%) than in the TAU group (98.6%; 95% CI, 96.6%-100%; P<0.001). The median latency period was 26 days and 15 days in the CBT and TAU groups, respectively (hazard ratio, 0.16; 95% CI, 0.12-0.22; P<0.001). CBT significantly reduced ≥ grade 3 oral mucositis (71.9% vs. 22.5%, P<0.001), dry mouth (10.8% vs. 3.7%, P=0.021), dysphagia (18% vs. 5.1%, P=0.001), and oral pain (10% vs. 3.6%, P=0.034) compared with TAU. Patients receiving CBT and TAU during CCRT had similar short-term response rates. CONCLUSIONS: CBT reduced the occurrence, latency, and severity of oral mucositis in patients with LA-NPC during CCRT. Frontiers Media S.A. 2023-06-07 /pmc/articles/PMC10282775/ /pubmed/37350940 http://dx.doi.org/10.3389/fonc.2023.1143401 Text en Copyright © 2023 He, Xiao, Jiang, Wu, Liu, Fan, Ye, Zhao, Wu, Li, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
He, Li-li
Xiao, Shuai
Jiang, Cui-hong
Wu, Xiang-wei
Liu, Wen
Fan, Chang-gen
Ye, Xu
Zhao, Qi
Wu, Wen-qiong
Li, Yan-xian
Wang, Hui
Liu, Feng
A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
title A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
title_full A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
title_fullStr A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
title_full_unstemmed A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
title_short A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
title_sort randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282775/
https://www.ncbi.nlm.nih.gov/pubmed/37350940
http://dx.doi.org/10.3389/fonc.2023.1143401
work_keys_str_mv AT helili arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT xiaoshuai arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT jiangcuihong arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT wuxiangwei arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT liuwen arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT fanchanggen arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT yexu arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT zhaoqi arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT wuwenqiong arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT liyanxian arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT wanghui arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT liufeng arandomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT helili randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT xiaoshuai randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT jiangcuihong randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT wuxiangwei randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT liuwen randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT fanchanggen randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT yexu randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT zhaoqi randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT wuwenqiong randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT liyanxian randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT wanghui randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy
AT liufeng randomizedcontrolledtrialtoinvestigatecognitivebehavioraltherapyinpreventionandtreatmentofacuteoralmucositisinpatientswithlocoregionaladvancednasopharyngealcarcinomaundergoingchemoradiotherapy